Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795503 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL25264497 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL28985161 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL671071 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL98729 | 0.87 | AKR1B1 (0.33) | LMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL28197 | 0.87 | AKR1B1 (0.33) | LMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL27561548 | 0.87 | AKR1B1 (0.33) | LMNAL3MBTL1TDP1AKR1B1 | |
| Water SCHEMBL28186002 | 0.85 | AKR1B1 (0.32) | LMNAL3MBTL1AKR1B1 | |
| SCHEMBL968310 | 0.81 | LMNA (0.42) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL457880 | 0.81 | LMNA (0.42) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119744179-A | Conjugates for targeted therapy | 梁碧惠 | 2025-04-01 | — | — | CN | claimed |
| EP-4504267-A1 | CONJUGATE FOR TARGETING THERAPY | National Taiwan University (TW) | 2025-02-12 | — | — | EP | claimed |
| WO-2023195839-A1 | CONJUGATE FOR TARGETING THERAPY | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-12 | — | — | WO | claimed |
| US-20230310618-A1 | CONJUGATE FOR TARGETING THERAPY | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-05 | — | — | US | claimed |
| EP-2445506-B1 | THE USE OF SPINOSYNS AND SPINOSYN COMPOSITIONS AGAINST DISEASES CAUSED BY PROTOZOANS, VIRAL INFECTIONS AND CANCER | ENTARCO SA (GR) | 2014-12-31 | — | — | EP | claimed |
| US-8653043-B2 | Enhanced neoglycosides through neoglycosylation and methods of use thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-18 | — | — | US | claimed |
| US-20130184330-A1 | COMPOSITIONS AND METHODS FOR INDUCING CANCER CELL DEATH | UNIVERSITY OF MIAMI (US) | 2013-07-18 | — | — | US | claimed |
| US-20120108530-A1 | Enhanced Neoglycosides Through Neoglycosylation and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-03 | — | — | US | claimed |
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-04-19 | — | — | US | claimed |
| WO-2012024234-A1 | COMPOSITIONS AND METHODS FOR INDUCING CANCER CELL DEATH | UNIVERSITY OF MIAMI (US) | 2012-02-23 | — | — | WO | claimed |
| US-20120039805-A1 | Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample | PANGEA BIOSCIENCES, INC. | 2012-02-16 | — | — | US | claimed |
| WO-2010096627-A1 | THERAPEUTICS AND METHODS FOR TREATING NEOPLASTIC DISEASES COMPRISING DETERMINING THE LEVEL OF CAVEOLIN-1 AND/OR CAVEOLIN-2 IN A STROMAL CELL SAMPLE | LISANTI MICHAEL P (US) | 2010-08-26 | — | — | WO | claimed |
| WO-2010080863-A1 | ENHANCED NEOGLYCOSIDES THROUGH NEOGLYCOSYLATION AND METHODS OF USE THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | WO | claimed |
| EP-1322304-A4 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | LAMPIDIS THEODORE J (US) | 2008-06-25 | — | — | EP | claimed |
| US-7160865-B2 | Heterocyclic alcohols such as 2-deoxy-D-glucose or 5-thio-D-glucose, used as anticarcinogenic agents or angiogenesis inhibitors; glycolysis antagonists | LAMPIDIS THEODORE J | 2007-01-09 | — | — | US | claimed |
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J | 2006-02-02 | — | — | US | claimed |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J (US) | 2005-02-24 | — | — | US | claimed |
| EP-1322304-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | Lampidis, Theodore J. (US) | 2003-07-02 | — | — | EP | claimed |
| WO-2001082926-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | LAMPIDIS THEODORE J (US) | 2001-11-08 | — | — | WO | claimed |
| WO-1998025940-A1 | INHIBITORS OF GLYCOSYLTRANSFERASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | LMNA 4687/4885L3MBTL1 941/4885TDP1 2578/4885 |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | LMNA 4687/4885L3MBTL1 941/4885TDP1 2578/4885 |
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | CD22, UGGT1, UGCG | LMNA 4698/4885L3MBTL1 264/4885TDP1 3929/4885 |
| US-20120108530-A1 | Enhanced Neoglycosides Through Neoglycosylation and Methods of Use Thereof | BET1, GALE, ENGASE | LMNA 3923/4885L3MBTL1 2087/4885TDP1 2444/4885 |
| US-20230310618-A1 | CONJUGATE FOR TARGETING THERAPY | FOLH1, CD44, SLC10A1 | LMNA 3750/4885L3MBTL1 1068/4885TDP1 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.